Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STEADY acute ischemic stroke thrombolysis registry in Hubei Province
ChiCTR2300071671Phase 4Not yet recruiting
- Sponsor
- Tongji Hospital
- Start
- Mar 2023
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of tenecteplase, tissue-plasminogen activator and urokinase in ischemic stroke (3 arms), sponsored by Tongji Hospital. Primary endpoints: Favorable functional outcome at 90 days and Analysis of thrombolysis delay. Planned start Mar 2023; status: not yet recruiting.
02
Drugs
tenecteplasetissue-plasminogen activatorurokinase
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on ChiCTR2300071671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300071671.